Bayer in another Japanese molecular imaging deal
This article was originally published in Scrip
Bayer Schering Pharma(BSP) has licensed exclusive global development and marketing rights to a group of cancer imaging molecules developed by the Japanese firm Hamamatsu Photonics. The radionucleotide-labelled tracers are taken up by carrier molecules highly expressed on malignant tumour cells and are used in combination with positron emission tomography (PET). The hope is that they will aid earlier and more specific identification of malignant cells, BSP said. It is the second Japanese imaging alliance in recent months for the German group. Last year, BSP acquired from Nagasaki University similar rights to molecules used in the PET imaging and diagnosis of Alzheimer's disease (Scrip Online, September 12th, 2009).
You may also be interested in...
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.